Non-small cell lung cancer stage II

8 trials 6 recruiting MedDRA PT
8 Registered trials
6 Recruiting
7 Unique sponsors
15 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 6
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Antibody-drug conjugate (ADC) 2 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (PD-L1) 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Immunosuppressant 1 substance
Monoclonal antibody 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 4 Phase II: 3 Phase I (Other): 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

4 trials
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-506696-10-00 12 countries 2024 n=576
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-508012-35-00 13 countries 2024 n=258
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    DURVALUMAB
    2023-508773-82-00 7 countries 2025 n=335
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    CEMIPLIMAB
    2024-519901-36-00 7 countries 2025 n=300
    Recruiting

Phase II

3 trials
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; DURVALUMAB; FALBIKITUG; INFLIXIMAB; MONALIZUMAB; MYCOPHENOLATE MOFETIL; OLECLUMAB; RILVEGOSTOMIG; VOLRUSTOMIG
    2023-508852-21-00 7 countries 2022 n=493
    Recruiting
  • Innate Pharma Commercial
    DURVALUMAB; IPH5201
    2023-507778-42-00 4 countries 2023 n=69
    Recruiting
  • AIO-Studien gGmbH Academic
    SACITUZUMAB GOVITECAN; ZIMBERELIMAB
    2024-517561-16-00 1 country n=50
    Pending

Phase I (Other)

1 trial
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
ETOP IBCSG Partners Foundation Academic 2 Phase III 2
Systimmune Inc. Commercial 1 Phase I (Other) 1
AstraZeneca AB Commercial 1 Phase II 1
Innate Pharma Commercial 1 Phase II 1
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 1
AIO-Studien gGmbH Academic 1 Phase II 0
New trials by year
2022
1
2023
1
2024
2
2025
3
← All indication landscapes